A Study of Ascending Single Doses of Surotomycin in Healthy Participants (MK-4261-008)

Inclusion Criteria: * Has no evidence of prior chronic gastrointestinal inflammatory disease such as inflammatory bowel disease or gastroesophageal reflux disease documented on endoscopy * Electrocardiogram (ECG) shows no clinically significant abnormalities * Is able to swallow capsules * is in good health Exclusion Criteria: * Pregnant or lactating females * Has had Clostridium (C.) difficile disease within 1 year prior to entry into the study * Has received an investigational drug or participated in any experimental procedure within1 month prior to study entry and at least 6 half lives from last intake of study drug * Participants 18 to 49 years of age had taken any regular, prescribed, or over-the-counter medication * Has any significant concurrent therapies * Has a positive drug screen * Has a positive human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C screen * Has given more than 450 mL of blood (one unit) in the 60 days preceding screening * Is an active intravenous drug user or abuses alcohol * Has had a malignancy within the last 5 years * Has inadequate protection against pregnancy during the conduct of the study and until 1 month after last dose of study drug * Has received any antibiotics within 30 days prior to first dose of study drug * Has been hospitalized within the past 30 days prior to Study Day 1 * Has known hypersensitivity to daptomycin